Referenzen

1. Motzer RJ, Hutson TE, Cella D, et al.: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722–31.
2. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24.
3. Grünwald V, Lin X, Kalanovic D, et al.: Tumor response is an independent prognostic factor in patients (pts) treated for metastatic renal cell carcinoma (mRCC) [ESMO abstract 2702]. In European Society for Medical Oncology 2013.
4. Rini BI, Plimack ER, Stus V, et al.: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380: 1116–27.
5. Motzer RJ, Penkov K, Haanen J, et al.: Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380: 1103–15.
6. Lacouture ME, Mitchell EP, Piperdi B, et al.: Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351–7.
7. Basch E, Deal AM, Dueck AC, et al.: Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA 2017; 318: 197.